A drug being developed by Roche Holding and biotech firm Plexxikon reduced tumor size in 70% of melanoma patients with a mutated BRAF gene, while about 40% of those without the mutation showed no response, researchers found during an early-stage clinical trial. The compound, PLX4032, is expected to undergo a Phase II trial by the end of this year.

Full Story:

Related Summaries